Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Rhode Island Hospital

Providence, Rhode Island 02903, United StatesRhode Island Hospital

178running trials
69closed trials

Part of

Rhode Island Hospital

Trial registries list Rhode Island Hospital under 22 sites and names; the figures below count all of them.

283trials across all its sites
194of them running
22registry sites and names
21,231publications (OpenAlex)

Type (ROR): Healthcare
Website: rhodeislandhospital.org
Publishes most on: Lyme disease

See all 283 trials at Rhode Island Hospital

Institution data from ROR and OpenAlex, trial counts from the trial registries.

The trials here

What the 254 trials at this site are about, from their registry records.

Conditions: Childhood cancers83 trials
Lung cancer26 trials
Acute myeloid leukaemia19 trials
Sarcoma19 trials
Acute lymphoblastic leukaemia18 trials
Kidney cancer16 trials
Colorectal cancer14 trials
Alzheimer disease12 trials
Coronary artery disease12 trials
Pancreatic cancer11 trials
Stroke11 trials
Neuroblastoma10 trials
and 52 more
Phase: Phase 397 trials
Phase 261 trials
Phase 113 trials
Phase 1/211 trials
Phase 2/36 trials
Phase 42 trials
Early phase 11 trial
Status: Active, not recruiting101 trials
Recruiting67 trials
Completed62 trials
Not yet recruiting8 trials
Suspended7 trials
Terminated6 trials
Enrolling by invitation2 trials
Withdrawn1 trial
Lead sponsor: National Cancer Institute (NCI)59 trials
Children's Oncology Group47 trials
Rhode Island Hospital14 trials
Alliance for Clinical Trials in Oncology12 trials
Brown University5 trials
and 91 more

Running trials

Not yet recruiting
Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias
NCT07933367· Rhode Island Hospital· Source
Contact: Laura Korthauer, Ph.D.
Not yet recruiting
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
NCT07502872· Phase 2· Brown University· Source
Contact: Roxanne Wood
Not yet recruiting
Digital Intervention Delivered Via Street Medicine to Increase HIV and Substance Use Care Among Survivors of Sex Trafficking
NCT07699484· Early phase 1· Lifespan· Source
Contact: Lindsay Orchowski, PhD
Recruiting
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
NCT06917911· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Recruiting
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT07437950· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Not yet recruiting
Nurse-Led PrEP Initiation Among Incarcerated Individuals
NCT07781423· Rhode Island Hospital· Source
Contact: Evan Ames
Recruiting
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
NCT07805954· Phase 3· Revolution Medicines, Inc.· Source
Contact: Andrew Schumacher
Not yet recruiting
Verapamil Effect in Cystic Fibrosis-related Dysglycemia
NCT07688070· Phase 2· Rhode Island Hospital· Source
Contact: Kevin J Scully
Recruiting
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
NCT07466316· Phase 3· Children's Oncology Group· Source
Contact: Bradley DeNardo (principal investigator)
Recruiting
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Thomas Ollila (principal investigator)
Recruiting
Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well
NCT07115940· Amrou Sarraj· Source
Contact: Wendy Smith, BS, RTRCV, CCRP
Enrolling by invitation
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
NCT06773936· Phase 2· SWOG Cancer Research Network· Source
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Boris Martinez (principal investigator)
Recruiting
Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome
NCT07144631· Rhode Island Hospital· Source
Contact: Vesna Buntak, MD
Recruiting
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
NCT05630794· Phase 1· National Cancer Institute (NCI)· Source
Contact: Alexander G. Raufi
Recruiting
IVUS CHIP UPP Registry
NCT06625801· ECRI bv· Source
Contact: Chantal Bakker
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Sherise Rogers (principal investigator)
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
NCT06959524· Boston Scientific Corporation· Source
Contact: Jinnette Dawn Abbott, MD
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· National Cancer Institute (NCI)· Source
Contact: Bradley DeNardo (principal investigator)
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· National Cancer Institute (NCI)· Source
Contact: Bradley DeNardo (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Ariana Santopietro (principal investigator)
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development Inc.
Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Recruiting
Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health
NCT07011563· Rhode Island Hospital· Source
Contact: Jack Rusley, MD, MHS
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: Bradley DeNardo (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Bradley DeNardo (principal investigator)
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Recruiting
StrokeNet Thrombectomy Endovascular Platform
NCT06289985· Medical University of South Carolina· Source
Contact: Jordan Elm
Recruiting
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212· Phase 3· Rakuten Medical, Inc.· Source
Contact: Sopha Dionson
Recruiting
The Puerto Rico Asthma Integrated Response Program ("PR-AIR")
NCT05999032· Rhode Island Hospital· Source
Contact: Daphne Koinis Mitchell, PhD
Active, not recruiting
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· Phase 3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Brain and Behavior Influences on Obesity Development From Infancy Through Childhood
NCT06861868· Johns Hopkins University· Source
Contact: Viren D'Sa, MD
Active, not recruiting
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960· CereVasc Inc· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706· Phase 2· Eli Lilly and Company· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Adam J. Olszewski (principal investigator)
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· Phase 2· Children's Oncology Group· Source
Contact: Bradley DeNardo (principal investigator)
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Recruiting
Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass
NCT07132788· University of Pennsylvania· Source
Contact: Allyson Sherman-Roe Senior Clincial Research Program Coordinator
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180· Phase 3· Replimune, Inc.· Source
Contact: Maria Constantinou, MD (principal investigator)
Active, not recruiting
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662· Phase 1· Pfizer· Source
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: John L. Reagan (principal investigator)
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Bradley DeNardo (principal investigator)
Active, not recruiting
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360· Phase 2· Weill Medical College of Cornell University· Source
Recruiting
Strategy for Improving Stroke Treatment Response
NCT05948566· Phase 2· Translational Sciences, Inc.· Source
Contact: Farhan Khan, MD
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698· Hamilton Health Sciences Corporation· Source
Contact: Ana-Lucia Garcia-Guarniz, MD (principal investigator)
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645· Children's Oncology Group· Source
Contact: Bradley DeNardo (principal investigator)
Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685· Phase 1/2· Indapta Therapeutics, INC.· Source
Contact: Stephen Donnelly

Showing 50 of 178.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers25 recruiting
Acute myeloid leukaemia10 recruiting
Acute lymphoblastic leukaemia9 recruiting
Lung cancer5 recruiting
Sarcoma5 recruiting
Stroke5 recruiting
Coronary artery disease4 recruiting
Chronic lymphocytic leukaemia3 recruiting
Down syndrome3 recruiting
High blood pressure3 recruiting
HIV3 recruiting
Myelodysplastic syndromes3 recruiting
Myeloproliferative neoplasms3 recruiting
Ovarian cancer3 recruiting
Pancreatic cancer3 recruiting
Alzheimer disease2 recruiting
Atrial fibrillation2 recruiting
Colorectal cancer2 recruiting
Cystic fibrosis2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Follicular lymphoma2 recruiting
Head and neck cancer2 recruiting
Kidney cancer2 recruiting
Mantle cell lymphoma2 recruiting
Multiple myeloma2 recruiting
Neuroblastoma2 recruiting
Prostate cancer2 recruiting
Pulmonary arterial hypertension2 recruiting
Triple-negative breast cancer2 recruiting
Aortic stenosis1 recruiting
Chronic myeloid leukaemia1 recruiting
Endometrial cancer1 recruiting
Frontotemporal dementia1 recruiting
Gastric and oesophageal cancer1 recruiting
Hearing loss1 recruiting
Heart failure1 recruiting
Hodgkin lymphoma1 recruiting
Insomnia1 recruiting
Melanoma1 recruiting
Neuroendocrine tumours1 recruiting
Obesity1 recruiting
Restless legs syndrome1 recruiting

Closed trials

Completed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Completed
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
NCT05829226· Phase 1· PureTech· Source
Completed
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839· Phase 1/2· Dragonfly Therapeutics· Source
Completed
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
NCT05357989· Phase 3· Annovis Bio Inc.· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Gilead Sciences· Source
Completed
Impact of Sleep Duration on Immune Balance in Urban Children With Asthma
NCT05420766· Rhode Island Hospital· Source
Withdrawn
Combined Injectable Treatment for HIV and OUD
NCT05991622· Phase 2· Rhode Island Hospital· Source
Terminated
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
NCT05220722· Phase 1/2· TriSalus Life Sciences, Inc.· Source
Terminated
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
NCT03919162· Phase 2· Vivoryon Therapeutics N.V.· Source
Completed
Intelligent Spine Interface, Clinical (ISI-C)
NCT04302259· Rhode Island Hospital· Source
Completed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
NCT04921969· Phase 3· Incyte Corporation· Source
Completed
Removing Transfusion Dependence as a Barrier to Hospice Enrollment
NCT05063591· Adam Olszewski· Source
Completed
Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy
NCT04693715· Phase 2· Revalesio Corporation· Source
Completed
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
NCT04801420· Phase 2· Pfizer· Source
Completed
Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation
NCT04702451· Volta Medical· Source
Completed
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844· NovoCure Ltd.· Source
Completed
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
NCT04640077· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
NCT04266795· Phase 2· Takeda· Source
Completed
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029· Phase 1· Dragonfly Therapeutics· Source
Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404· Duke University· Source
Contact: Chi Hornik
Terminated
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· Phase 3· Biogen· Source
Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046· Phase 3· Yale University· Source
Contact: Kevin N Sheth, MD
Completed
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
NCT03374332· Phase 1/2· Brown University· Source
Completed
Study of DF1001 in Patients With Advanced Solid Tumors
NCT04143711· Phase 1/2· Dragonfly Therapeutics· Source
Completed
A Mobile Gaming App to Improve ART Adherence for Youth
NCT03760211· Rhode Island Hospital· Source
Completed
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03702725· Phase 1· Alliance Foundation Trials, LLC.· Source
Completed
ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease
NCT03622905· Functional Neuromodulation Ltd· Source
Completed
TRC-PAD Program: In-Clinic Trial-Ready Cohort
NCT04004767· University of Southern California· Source
Completed
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
NCT03677154· Phase 1/2· Hoffmann-La Roche· Source
Terminated
Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care
NCT03762655· InVivo Therapeutics· Source
Completed
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
NCT03589547· Phase 2· Brown University· Source
Completed
Peer-Administered Asthma Self-Management Intervention in Urban Middle Schools
NCT03446365· Rhode Island Hospital· Source
Completed
Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)
NCT03771508· Medtronic - MITG· Source
Completed
Rhode Island Asthma Integrated Response Program
NCT03583814· Rhode Island Hospital· Source
Completed
Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry
NCT03048825· Phase 3· Population Health Research Institute· Source
Completed
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
NCT03206450· Children's Oncology Group· Source
Completed
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
NCT03168776· Sino Medical Sciences Technology Inc.· Source
Completed
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02873195· Phase 2· Academic and Community Cancer Research United· Source
Completed
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03072238· Phase 3· Hoffmann-La Roche· Source
Completed
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358· Phase 2· National Cancer Institute (NCI)· Source
Completed
Alzheimer's Disease Neuroimaging Initiative 3
NCT02854033· University of Southern California· Source
Completed
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
NCT02831959· Phase 3· NovoCure GmbH· Source
Completed
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02470091· Phase 2· Children's Oncology Group· Source
Completed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718· Phase 3· Hoffmann-La Roche· Source
Completed
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
NCT02412228· Phase 2· John L. Reagan· Source
Completed
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source
Completed
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT01805076· Phase 3· Alliance for Clinical Trials in Oncology· Source
Completed
Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms
NCT02009644· Bolton Medical· Source
Completed
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
NCT01979536· Phase 2· National Cancer Institute (NCI)· Source

Showing 50 of 69.

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error